Claes Malm

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

Gunnar Juliusson, Fredrik Celsing, Ingemar Turesson et al. · British Journal of Haematology · 2000 · 245 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

Magnus Björkholm, Åsa Rangert Derolf, Malin Hultcrantz et al. · Journal of Clinical Oncology · 2011 · 244 citations · Full text

Medicine, Oncology, Pharmacology +14

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn et al. · Blood · 2011 · 194 citations · Full text

Medicine, Hematology, Oncology +10

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Martin Höglund, Fredrik Sandin, Karin Hellström et al. · Blood · 2013 · 127 citations

Medicine, Oncology, Pharmacotherapy +13

Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies

Magnus Vrethem, Mabel Cruz, Claes Malm et al. · Journal of the Neurological Sciences · 1993 · 77 citations

Medicine, Neurology, Neuroscience +14